Syra Health Corp. Class A (SYRA) Income Statement
SYRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSYRA revenue and net income
Where SYRA's revenue goes
2025Each bar shows an amount and its share of revenue. SYRA kept −12.4% of revenue as net income.
SYRA profit margins
SYRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −9.5% | +8.8% | — | — |
| Gross profit | +50.5% | +32.8% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SYRA quarterly EPS vs estimates
Syra Health Corp. Class A beat the analyst EPS estimate in 3 of the last 8 quarters.
SYRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $7.2M | $8.0M | $5.5M | $5.6M | $1.4M | $0 |
| Cost of revenue | $4.7M | $6.3M | $4.1M | $4.6M | $979,622 | — |
| Gross profit | $2.5M | $1.7M | $1.4M | $1.1M | $430,354 | — |
| Research & development | $67,840 | $585,146 | $240,048 | $0 | — | — |
| Sales, general & admin | $3.3M | $4.8M | $4.0M | $3.1M | $416,009 | — |
| Total operating expenses | $3.4M | $5.4M | $4.3M | $3.2M | $433,634 | $4,267 |
| Operating income | −$904,324 | −$3.8M | −$2.9M | −$2.1M | −$3,280 | −$4,267 |
| Interest income | $21,261 | $21,247 | $2,942 | $63 | $0 | — |
| Interest expense | $13,270 | $15,600 | $53,686 | $28,533 | $0 | — |
| Income before taxes | −$896,333 | −$3.8M | −$2.9M | −$2.1M | −$3,280 | −$4,267 |
| Income taxes | — | −$3.8M | $2,942 | $63 | — | −$51,204 |
| Net income | −$896,333 | −$3.8M | −$2.9M | −$2.1M | −$3,280 | −$4,267 |
| EBITDA | −$862,595 | −$3.7M | −$2.8M | −$2.1M | −$3,073 | −$4,267 |
| EPS (diluted) | −$0.07 | −$0.51 | −$0.24 | −$0.41 | $0.00 | — |
| Gross margin | 34.4% | 20.7% | 25.5% | 18.9% | 30.5% | — |
| Operating margin | −12.5% | −47.2% | −52.4% | −37.2% | −0.2% | — |
| Net margin | −12.4% | −47.1% | −53.3% | −37.7% | −0.2% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.3M | $1.7M | $1.7M | $1.9M | $1.9M | $2.0M | $2.3M | $2.0M | $1.8M | $1.8M | $1.6M |
| Cost of revenue | $1.3M | $1.3M | $1.1M | $1.1M | $1.2M | $1.3M | $1.6M | $1.6M | $1.6M | $1.5M | $1.2M | $1.0M |
| Gross profit | $1.1M | $971,255 | $591,170 | $554,541 | $752,895 | $589,156 | $455,371 | $668,298 | $350,007 | $299,779 | $582,044 | $554,541 |
| Research & development | $47,351 | $6,921 | $139 | $816 | $29,712 | $37,173 | $5,117 | $34,821 | $277,894 | $277,548 | $240,048 | — |
| Sales, general & admin | $766,640 | $772,297 | $724,395 | $780,500 | $780,363 | $1.0M | $954,878 | $288,305 | $1.4M | $1.5M | $1.3M | $885,200 |
| Total operating expenses | $814,732 | $780,272 | $726,831 | $786,712 | $816,053 | $1.1M | $957,039 | $1.1M | $1.7M | $1.7M | $1.6M | $897,557 |
| Operating income | $251,571 | $190,983 | −$135,661 | −$232,171 | −$63,158 | −$473,334 | −$501,668 | −$428,910 | −$1.4M | −$1.4M | −$986,154 | −$343,016 |
| Interest income | $888 | $52,458 | $5,369 | $8,174 | $3,420 | $4,298 | $2,799 | $13,641 | $3,826 | $981 | $116 | $2,820 |
| Interest expense | $2,217 | $2,462 | $4,278 | $1,905 | $3,858 | $3,229 | $5,528 | $2,266 | $3,729 | $4,077 | $9,237 | $14,180 |
| Income before taxes | $250,242 | $240,979 | −$134,570 | −$225,902 | −$63,596 | −$472,265 | −$504,397 | −$417,535 | −$1.4M | −$1.4M | −$995,275 | −$354,376 |
| Income taxes | — | — | — | — | — | — | — | −$25,541 | −$4 | $4,077 | $116 | $2,820 |
| Net income | $250,242 | $240,979 | −$134,570 | −$225,902 | −$63,596 | −$472,265 | −$504,397 | −$417,535 | −$1.4M | −$1.4M | −$995,275 | −$354,376 |
| EBITDA | $251,571 | $244,495 | −$127,995 | −$221,806 | −$53,760 | −$462,239 | −$491,591 | −$389,728 | −$1.4M | −$1.4M | −$973,680 | −$327,839 |
| EPS (diluted) | — | — | $0.00 | −$0.02 | −$0.01 | −$0.04 | −$0.02 | −$0.06 | −$0.21 | −$0.22 | −$0.16 | −$0.08 |
| Gross margin | 44.5% | 42.7% | 34.1% | 32.9% | 38.7% | 31.7% | 22.7% | 29.7% | 17.8% | 17.1% | 33.0% | 35.1% |
| Operating margin | 10.5% | 8.4% | −7.8% | −13.8% | −3.2% | −25.5% | −25.0% | −19.0% | −70.6% | −82.4% | −55.8% | −21.7% |
| Net margin | 10.5% | 10.6% | −7.8% | −13.4% | −3.3% | −25.4% | −25.1% | −18.5% | −70.6% | −82.6% | −56.4% | −22.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SYRA's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SYRA financial results
In fiscal year 2025 (ended December 31, 2025), Syra Health Corp. Class A reported revenue of $7.2 million, down 9.5% from the year before. It had a net loss of $0.9 million, a net profit margin of −12.4%. Diluted earnings per share came to −$0.07.
See the SYRA stock overview for the latest quote and news, or the SYRA chart for price history and technical indicators.
SYRA income statement FAQ
What is Syra Health Corp. Class A's annual revenue?
Syra Health Corp. Class A reported total revenue of $7.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 9.5% from $8.0 million the previous year.
Is Syra Health Corp. Class A profitable?
No. Syra Health Corp. Class A reported a net loss of $0.9 million in fiscal 2025, a net profit margin of −12.4%; its operating margin was −12.5%.
What is Syra Health Corp. Class A's gross margin?
Syra Health Corp. Class A's gross margin was 34.4% in fiscal 2025: for every $100 of revenue, Syra Health Corp. Class A kept $34 after the direct cost of its products and services.
How much does Syra Health Corp. Class A spend on research and development?
Syra Health Corp. Class A spent $0.1 million on research and development in fiscal 2025, 0.9% of revenue.
What are Syra Health Corp. Class A's earnings per share?
Syra Health Corp. Class A earned $-0.07 per diluted share in fiscal 2025, compared with $-0.51 a year earlier.
When does Syra Health Corp. Class A's fiscal year end?
Syra Health Corp. Class A's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.